Acer Therapeutics to Participate in January 2022 Virtual Investor Conferences

Rhea-AI Summary

Acer Therapeutics Inc. (Nasdaq: ACER) announced participation in the upcoming 11^th Annual LifeSci Partners Corporate Access virtual event and the H.C. Wainwright Global BioConnect Virtual Conference. The LifeSci event will feature one-on-one virtual meetings from January 5-7, 2022, while the H.C. Wainwright conference will present on-demand recordings on January 10, 2022. Acer focuses on developing therapies for serious rare diseases, with a diverse pipeline including ACER-001 for metabolic disorders and ACER-801 for induced vasomotor symptoms.

NEWTON, Mass., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that Acer’s management team will participate in the upcoming 11^th Annual LifeSci Partners Corporate Access virtual event and the H.C. Wainwright BioConnect Virtual Conference.

Conference:	11th Annual LifeSci Partners Corporate Access virtual event
Format:	One-on-one virtual meetings
Dates:	January 5-7, 2022
Register:	https://www.meetmax.com/sched/event_78427/invitee_login.html
Conference:	H.C. Wainwright Global BioConnect Virtual Conference
Format:	On-demand recorded corporate presentation
Dates:	January 10, 2022
Webcast:	https://journey.ct.events/view/b30c9e23-05f3-4bc7-8e05-675b2cfa5a88

About Acer Therapeutics Inc.
Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. Acer’s pipeline includes four programs: ACER-001 (sodium phenylbutyrate) for treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); ACER-801 (osanetant) for treatment of induced Vasomotor Symptoms (iVMS); EDSIVO™ (celiprolol) for treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. Each of Acer’s product candidates is believed to present a comparatively de-risked profile, having one or more of a favorable safety profile, clinical proof-of-concept data, mechanistic differentiation and/or accelerated paths for development through specific programs and procedures established by the FDA. In March 2021, Acer entered into a Collaboration and License Agreement with Relief for development and commercialization of ACER-001. For more information, visit www.acertx.com.

Investor Contact:
Hans Vitzthum
LifeSci Advisors
Ph: 617-430-7578
hans@lifesciadvisors.com

Jim DeNike
Acer Therapeutics Inc.
Ph: 844-902-6100
jdenike@acertx.com

FAQ

What events is Acer Therapeutics participating in January 2022?

Acer Therapeutics will attend the 11th Annual LifeSci Partners Corporate Access virtual event from January 5-7, 2022, and the H.C. Wainwright Global BioConnect Virtual Conference on January 10, 2022.

What is the format of the LifeSci Partners Corporate Access event?

The LifeSci Partners Corporate Access event will feature one-on-one virtual meetings.

When does the H.C. Wainwright Global BioConnect Virtual Conference take place?

The H.C. Wainwright Global BioConnect Virtual Conference will be held on January 10, 2022.

How can I register for the Acer Therapeutics events?

You can register for the events through the link provided in the announcement: https://www.meetmax.com/sched/event_78427/invitee_login.html.

What therapies does Acer Therapeutics focus on?

Acer Therapeutics focuses on therapies for serious rare and life-threatening diseases, including ACER-001 for metabolic disorders and ACER-801 for induced vasomotor symptoms.